Why QA and QP Capacity Is Becoming the Hidden Bottleneck in Advanced Therapy Manufacturing

This is the conversation we are increasingly having with operational leaders across Switzerland, Germany, and the Netherlands. Manufacturing investment is accelerating. Quality infrastructure is not keeping pace.

The scale of the advanced therapy sector is no longer a projection it is a present-day operational reality. There are currently 2,125 active cell and gene therapy clinical trials globally, with 335 in Europe alone. Across all modalities cell, gene, and RNA therapeutics that number reaches 3,243 trials worldwide, supported by 1,943 developers globally, 407 of whom are based in Europe.

As programmes advance from early clinical stages toward late-phase and commercial manufacturing, the operational load on quality systems compounds. More batches. More deviations. More change control. More regulatory interactions. More inspections.

The quality function that was adequate for a Phase I programme is rarely adequate for the same company two years later.

In Europe, the Qualified Person is not a process improvement initiative they are a legal requirement. No QP certification, no batch release, no shipment. This makes QP capacity a direct throughput constraint, not a supporting function. When QP bandwidth is stretched, manufacturing timelines slip regardless of how well the process runs.

Beyond QP certification, the broader quality and regulatory interaction burden in advanced therapies is considerable. ATMP development in Europe has generated 705 classification submissions and 704 scientific advice procedures to date. Each interaction creates downstream work for QA and CMC teams documentation, responses, follow-up, and change management. Companies underestimating this cadence consistently find their quality teams overwhelmed before commercial manufacturing even begins.

The August 2024 full applicability of EU GMP Annex 1 has added further pressure. Contamination control strategy requirements have increased across sterile manufacturing operations, meaning QA teams must now own and maintain more complex documentation frameworks, risk assessments, and monitoring programmes than before.

The shortage of experienced QA and QP professionals in advanced therapies is not simply a supply-and-demand imbalance. It is structural.

The skills required are genuinely specialised. A QA professional experienced in traditional small molecule manufacturing does not automatically transfer into cell therapy GMP without significant retraining. The same applies across modalities. Cell therapy, viral vectors, mRNA, antibody therapeutics, and radiopharmaceuticals each carry distinct regulatory expectations, process risks, and quality frameworks. Experience in one does not confer competence in another and hiring leaders in these sectors know it.

Geographical concentration adds another layer of difficulty. Clusters such as Basel, Munich, and Germany's biologics manufacturing hubs are competing for the same narrow talent pool. Sites near the Swiss border face an additional variable: compensation competition from Swiss organisations that consistently skews the local market. Candidates with the right profile often have multiple options, shorter decision timelines, and higher expectations than the market anticipated.

Across conversations with quality and operational leaders in scaling biotech companies and CDMOs, the pattern is consistent. Hiring demand is concentrating around senior QA managers, Qualified Persons, GMP compliance leaders, and inspection readiness specialists. These are not exploratory hires — they are operationally critical appointments where a vacancy carries direct timeline risk.

The expectation from hiring leaders has also shifted. Volume shortlists are not useful when you need a QP who has certified batches in a viral vector facility or a QA manager who has led an EMA inspection in an ATMP environment. What operational leaders consistently tell us they need is technical pre-qualification candidates who have done this before, in a comparable environment, at the right level of seniority.

The downstream consequences of a stretched quality function are well understood by anyone who has navigated them: batch release delays, accumulating deviation backlogs, weakened change control, inspection findings, and, in the worst cases, delayed market authorisations. In advanced therapies, where programmes are time-sensitive and clinical supply windows are narrow, these consequences translate directly into patient and financial impact.

Quality is not a cost centre in this environment. It is the rate-limiting step.

The companies we see navigating this well share a common approach: they treat quality hiring as a strategic decision, not a reactive one. They invest in QA and QP leadership ahead of regulatory milestones rather than in response to them. They recognise that finding the right QP for an ATMP environment takes time and that beginning that search when a batch is already waiting is the wrong starting point.

As advanced therapy pipelines continue to expand and more programmes approach commercial-scale manufacturing, quality functions will face increasing pressure. The teams that will scale successfully are the ones building quality infrastructure now not catching up later.

At Panda, we support advanced therapy companies across Switzerland, Germany, the Netherlands, and Belgium in building experienced QA and QP teams. If quality capacity is on your radar, we are happy to share what we are seeing in the market.